Premium
A correlation of serum C3DP levels with chemotherapeutic management of cancer patients
Author(s) -
Parsons Robert G.,
Hoch James A.,
Longmire Robert L.
Publication year - 1978
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197806)41:6<2099::aid-cncr2820410605>3.0.co;2-c
Subject(s) - medicine , chemotherapy , cancer , gastroenterology , disease , malignant disease , surgery , pathology
Serial serum C3DP levels of 33 patients at our institution have been followed for up to 10 months. Individuals experiencing periods free of symptoms and signs of proliferating or expanding malignant disease, had C3DP levels which remained below 150 μg/ml. Patients with active or recurrent disease, while on chemotherapy, had elevated C3DP values (>150 μg/ml). Serum C3DP values declined abruptly following treatment which resulted in major reduction of tumor mass. Decreases in C3DP levels from values above 150 μg/ml to values within the normal range (50–150 μg/ml) were observed during 89% (25/28) of the favorable clinical responses which have been followed with C3DP assays. Increases in C3DP levels from values within the normal range to values above 150 μg/ml were observed either prior to or coordinate with clinical symptoms of disease recurrence 83% of the time (10/12 cases). These studies suggest that serial C3DP determinations offer an excellent prognostic aid for evaluating the response of malignant tumors during chemotherapeutic management.